Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties.

IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.

On August 25, 2017, XOMA Corporation licensed the global commercial rights to gevokizumab to Novartis.

XOMA received an approximately $16 million upfront payment, and Novartis repaid in its entirety the approximately €12 million of debt owed by XOMA to Les Laboratoires Servier.

XOMA is eligible to receive up to $438 million in development, regulatory and commercial milestones plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab.